Open AccessEffects of Candesartan and Lisinopril on the Fibrinolytic System in Hypertensive Patients
Author(s) -
Hirschl Michael M.,
Bur Andreas,
Woisetschlaeger Christian,
Derhaschnig Ulla,
Laggner Anton N.
Publication year - 2007
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2007.06506.x
Subject(s) - candesartan , lisinopril , medicine , blood pressure , fibrinolysis , ambulatory blood pressure , endocrinology , ace inhibitor , cardiology , angiotensin converting enzyme , angiotensin ii
The effects of the angiotensin II receptor blocker candesartan and the angiotensin‐converting enzyme inhibitor lisinopril on the fibrinolytic system were investigated in a double‐blinded, prospective, randomized study. Seventy‐seven hypertensive patients taking candesartan (n=41) and lisinopril (n=36) with a systolic blood pressure >130 mm Hg and/or a diastolic blood pressure >80 mm Hg obtained by 24‐hour ambulatory blood pressure measurement were included in the study. Blood pressure, plasminogen activator inhibitor 1 (PAI‐1), tissue plasminogen activator (tPA), and the molar ratio of PAI‐1/tPA were determined before treatment and 6 weeks later. Blood pressure decreased in both groups (candesartan, 155/85 mm Hg to 140/84 mm Hg; P <.05; lisinopril, 152/85 mm Hg to 138/83 mm Hg; P <.05). The fibrinolytic balance was significantly different between treatment groups (molar ratio of PAI‐1/tPA: candesartan, 3.66 [2.2]; lisinopril, 5.44 [2.6]; P <.05). In contrast to lisinopril, the balance between coagulation and fibrinolytic activity shifted toward fibrinolysis during candesartan treatment.